Clinical trials to address the clinical and prognostic significance of the SGLT2 inhibitor’s influence on anemia are currently being designed, providing a promising avenue for future research and potential breakthroughs in the fields of diabetes management and cardiovascular care [27]. This evidence concerns the gene SLC5A2 and diabetes mellitus.